Clinical trials: Anti-PD-1
Solid Tumor
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in…
- Trial name
- NCT04866485
- Testing
- HBM4003 and pembrolizumab
- Volunteers
- 66 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Pancreatic Cancer
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
- Trial name
- NCT06941857
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
Solid Tumors
Study of JS001 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with advanced solid tumors.
- Trial name
- NCT02857166
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Melanoma
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT06190951
- Testing
- cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab
- Where
- 104 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Malignancies
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer.
- Trial name
- NCT03233139
- Testing
- Cemiplimab, Ipilimumab, Platinum-doublet chemotherapy
- Where
- 20 sites in Japan
- Volunteers
- 146 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced/Metastatic Solid Tumors
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with…
- Trial name
- NCT05405595
- Testing
- ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab)
- Where
- 21 sites in United States, China and 1 more
- Volunteers
- 186 people
- Sponsor
- Adagene Inc
Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Chest malignant solid tumor (mainly lung and esophageal cancer) is a common malignant tumor that seriously threatens the health of residents in China.
- Trial name
- NCT05044728
- Testing
- Anti-PD-1 antibody combined with Paclitaxel and carboplatin., Surgical treatment stage
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Liver Cancer, Sarcopenia
Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment
Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.
- Trial name
- NCT05443230
- Testing
- gait speed; ct scan; grip strength and chair stand test
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Merkel Cell Carcinoma
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
The primary objectives of this study are to assess 1) the safety and 2) efficacy of combining Anti-PD-1/PD-L1 blockade with palliative radiation therapy in patients with Stage IV Merkel Cell Carcinoma.
- Trial name
- NCT03988647
- Testing
- Pembrolizumab, Radiation Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased.
- Trial name
- NCT07244978
- Testing
- Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, Sample
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-small Cell Lung Cancer
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after…
- Trial name
- NCT06382129
- Testing
- BL-B01D1, Docetaxel
- Where
- China
- Volunteers
- 698 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Malignant Melanoma Stage III
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the…
- Trial name
- SWE-NEO (NCT06794775)
- Testing
- Nivolumab, Nivolumab + Ipilimumab
- Where
- 3 sites in Sweden
- Volunteers
- 128 people
- Sponsor
- Hildur Helgadottir
Solid Tumors
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults aged 18 and over or above legal age with different types of recurrent advanced cancer (solid tumors) that have spread to other parts of the body and that are accessible for injection and biopsy.
- Trial name
- NCT07395258
- Testing
- BI 3923948, Ezabenlimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Triple Negative Breast Cancer
Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) is among the most aggressive and lethal types of breast cancer, and currently available therapies have an unsatisfactory impact on patients' survival.
- Trial name
- AZALEA (NCT06690840)
- Testing
- Atezolizumab in combination with Cyclophosphamide and Vinorelbine
- Where
- 5 sites in Italy
- Volunteers
- 45 people
- Sponsor
- European Institute of Oncology
Obstructive Sleep Apnea, Non-small Cell Lung Cancer
Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer
This prospective, observational cohort study aims to explore the influence of obstructive sleep apnea(OSA) on the efficacy of PD-1-based immunotherapy in patients with non-small cell lung cancer(NSCLC).
- Trial name
- NCT04743752
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Hepatocellular Carcinoma, Hepatocellular Cancer
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Background: A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03785210
- Testing
- nivolumab, tadalafil, oral vancomycin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the efficacy of HLX10 combined with chemotherapy versus placebo combined with chemotherapy for neoadjuvant/adjuvant treatment of…
- Trial name
- NCT04139135
- Testing
- HLX10
- Where
- 15 sites in China
- Volunteers
- 642 people
- Sponsor
- Shanghai Henlius Biotech
Melanoma Metastatic, Locally Advanced Melanoma
Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma
This is a monocentric, prospective study evaluating the effectiveness in reducing immune-related adverse events, and translational study conducted on 20 patients with inoperable locally advanced or metastatic melanoma.
- Trial name
- MELA-IMPACT (NCT06880198)
- Testing
- Oral Impact®
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Melanoma Onlus
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.